Bristol, AstraZeneca gain FDA nod for diabetes drug

01/8/2014 | Family Practice News

Bristol-Myers Squibb and AstraZeneca obtained federal approval for dapagliflozin to be used in the treatment of type 2 diabetes. The drug, a sodium-glucose co-transporter 2 inhibitor, will be marketed as Farxiga. The approval requires post-marketing studies by the manufacturer to determine risks related to the drug.

View Full Article in:

Family Practice News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA